September 26, 2024

TerraTrust nominated for the DQS Sustainability Award 2024 in the “Sustainable Innovation” category

TerraTrust nominated for the DQS Sustainability Award 2024 in the “Sustainable Innovation” category

We are pleased to announce significant news: the first sustainable and biodegradable pregnancy test in Europe developed by Zamann Pharma Support, under the Terra Trust house brand, has been nominated for the prestigious DQS Sustainability Award 2024 in the “Sustainable Innovation” category. This nomination is a confirmation of their tireless commitment to environmental protection and sustainable innovation.

Every year, the DQS Sustainability Awards recognize companies that are pioneers in sustainability. It is one of the most important awards in the field of sustainability, recognizing companies, regardless of their size, for their innovative approaches to promoting environmental protection and social responsibility. This nomination is not only a recognition for Terra Trust, but underscores how necessary sustainable solutions have become in all areas of life, including the healthcare industry.

For Terra Trust, this nomination symbolizes much more than just a recognition of their technical innovation. It highlights the growing importance of environmental protection in a sector traditionally characterized by plastic waste and environmentally harmful disposables. Their product represents a new generation of pregnancy tests that protect the environment without compromising on quality or accuracy.

More Information in German / Original News:

Our latest News

discover more
VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering

VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering

The next-generation platform integrates VectorBuilder’s regulatory-compliant gene delivery technology with MaxCyte’s clinically validated electroporation platform to enable robust, scalable, and reliable clinical-grade cell engineering. Chicago, IL & Rockville, MD – June 23, 2026 – VectorBuilder, a global leader in gene delivery technologies and CDMO services, and MaxCyte, a leading, cell-engineering company providing enabling platform technologies to […]

LEEI-Platform eFIT is Available to Industry and Research

LEEI-Platform eFIT is Available to Industry and Research

KyooBe Tech is making its innovative vaccine development platform available to industry and research partners:Enabling faster and scalable vaccine production using Low-Energy Electron Irradiation (LEEI). Flexible Vaccine Manufacturing for Emerging Infectious Diseases Recent infectious disease events—from hantavirus outbreaks and meningitis cases to recurring disease outbreaks in livestock farming—highlight the need for flexibly scalable vaccine manufacturing […]

Dr. Felix Kommoss awarded the 2026 Rudolf Virchow Prize

Dr. Felix Kommoss awarded the 2026 Rudolf Virchow Prize

For his research on the development of rare malignant tumors in the hereditary DICER1 tumor predisposition syndrome, Dr. Felix Kommoss has been awarded the Rudolf Virchow Prize of the German Society of Pathology (Deutsche Gesellschaft für Pathologie, DGP) – the most prestigious research award in the field of pathology in Germany. Dr. Kommoss conducts research […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp